Sami-Sabinsa Group Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jun 2038
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Curcuminoid composition for therapeutic management of metabolic syndrome (US 11,707,438) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Mar 5, 2027The maintenance fee for Therapeutic compositions and methods for pulmonary fibrosis (US 11,744,807) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 1 fee due Sep 12, 2027The maintenance fee for Compositions for Managing Chronic Obstructive Pulmonary Disease (US 11,925,606) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Compositions for Targeting Receptor for Advanced Glycation End-Products (RAGE) in a Chronic Inflammatory Condition (US 11,957,728) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,413,318 | Compositions and methods for management of atrophic gastritis and colitis In force · From the USPTO record | In force | From the USPTO record | |
| US 10,959,980 | Bioactive molecules from oroxylum indicum and their therapeutic applications In force · From the USPTO record | In force | From the USPTO record | |
| US 11,202,810 | Stable probiotic composition for the management of lactose intolerance In force · From the USPTO record | In force | From the USPTO record | |
| US 11,299,706 | Microbial bioconversion of curcuminoids to calebin-A In force · From the USPTO record | In force | From the USPTO record | |
| US 11,045,517 | Composition for therapeutic management of hypomelanotic skin conditions In force · From the USPTO record | In force | From the USPTO record | |
| US 11,351,102 | Plant Actives and Their Anti-Pollution Effects Thereof In force · High confidence | In force | High confidence | |
| US 11,419,906 | Method and Composition for Therapeutic Management of Gluten Intolerance In force · High confidence | In force | High confidence | |
| US 11,491,119 | Curcuminoid composition and its therapeutic potential in managing lung fibrosis In force · From the USPTO record | In force | From the USPTO record | |
| US 11,707,438 | Curcuminoid composition for therapeutic management of metabolic syndrome In force · From the USPTO record | In force | From the USPTO record | |
| US 12,257,274 | Fructophilic lactic acid producing bacteria In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned